Status:

UNKNOWN

Effect of Mediterranean Diet in Dyslipidemic Patients

Lead Sponsor:

Gangnam Severance Hospital

Conditions:

Dyslipidemias

Eligibility:

All Genders

Phase:

NA

Brief Summary

The purpose of this randomized cross-over clinical trial is to examine the effects of Mediterranean diet based intervention on inflammation, metabolic risk and microbiome in patients with dyslipidemia...

Eligibility Criteria

Inclusion

  • One or more of this criteria (total cholesterol ≥ 200mg/dl, LDL- cholesterol ≥130 mg/dL, triglyceride ≥ 200mg/dl)
  • If woman of child bearing potential, agree to use effective contraception throughout the study period and 30 days after discontinuation of study drug
  • Able to speak and read Korean
  • Able to comply with all required study procedures and schedule
  • Willing and able to give written informed consent
  • Participants who are not participating in other clinical trials.

Exclusion

  • Participants with cancer treatment
  • Participants with uncontrolled hypertension (systolic blood pressure (SBP) \>180 mmHg, or diastolic blood pressure (DBP) \>120 mmHg)
  • Participants with uncontrolled diabetes or fasting glucose ≥ 200mg/dl)
  • Participants with hepatic disease (aspartate aminotransferase (AST)/alanine aminotransferase (ALT) \>3 x institutional upper limit of normal) or renal disease (serum creatinine \>2.0 mg/dL)
  • Participants with significant cardiovascular disease (ischemic heart disease or stroke)
  • Participants who are taking lipid-lowering medications.
  • Participants who are taking other clinical trial medications.
  • Participants with acute infectious disease such as pneumonia, acute gastroenteritis, and urinary tract infection.
  • Vegetarian (does not eat red meat, poultry or fish)
  • Participants with food allergy (sea food, fish, nuts, egg, meat, tomato, wheat, or soybean)
  • Participants who are not able to eat more than 10 mediterranean meal in a row.
  • Any condition which in the opinion of the investigator makes the subject unsuitable for inclusion in this study

Key Trial Info

Start Date :

April 24 2020

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

April 1 2021

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT04486664

Start Date

April 24 2020

End Date

April 1 2021

Last Update

July 24 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Gangnam Severance Hospital

Seoul, South Korea